About Spark Therapeutics
Spark Therapeutics is a Healthcare company based in Philadelphia (United States) founded in 2013, and was acquired by Roche in February 2019. Gene therapies for rare diseases including retinal dystrophies are developed. Spark Therapeutics has raised $82.8 million across 2 funding rounds from investors including Roche, Children's Hospital of Philadelphia and T. Rowe Price. The company has 822 employees. Spark Therapeutics has completed 1 acquisition, including Genable Technologies. Its focus areas include Life Sciences, Gene Therapy, DNA and dsDNA. Its legal entity is SPARK THERAPEUTICS, INC. Its competitors include Moderna, BridgeBio and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Spark Therapeutics was founded in 2013 and is headquartered in Philadelphia, United States. Focus is placed on the biotechnology sector, where gene therapies for rare diseases are developed. Engineered adeno-associated viruses are used to deliver target gene sequences for treating RPE-65 mediated inherited retinal dystrophies, choroideremia, hemophilia A and B, and neurodegenerative conditions such as Battens disease. Operations center on advancing these therapies through research and clinical development.
- Headquarters Philadelphia, United States
- Employees 822
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website sparktx.com
- Social LinkedIn X
- Acquired by Roche (Feb 2019)
- Legal Name Spark Therapeutics, Inc.
- Annual Revenue$64.73 M (USD)436as on Dec 31, 2018
- Net Profit-$78.82 M (USD)69as on Dec 31, 2018
- EBITDA-$193.64 M (USD)25as on Dec 31, 2018
- Total Equity Funding$82.8M (USD)
in 2 rounds
- Latest Funding Round$72.8M (USD), Series B
May 2014
- InvestorsRoche
& 7 more
- Employee Count822
- Investments & Acquisitions
- Acquired byRoche
(Feb 2019)
Funding Insights of Spark Therapeutics
Spark Therapeutics has successfully raised a total of $82.8M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $72.8 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $82.8M
- Total Rounds 2
- Last Round Series B — $72.8M
- First Round $10M
(Oct 2013)
- Investors Count 7
All 2 funding rounds of Spark Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | $72.8M | Series B | – | Sofinnova Investments | |
| Oct 2013 | $10M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Spark Therapeutics
Spark Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Children's Hospital of Philadelphia and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital firm focused on multiple sectors | brooksidecapital.com | San Francisco, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States | ||
Chain of pediatrics hospitals | 1855 | chop.edu | United States | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Spark Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Spark Therapeutics
774 people are tracked at Spark Therapeutics (335 in leadership, 5 in board & advisors, 434 in team); the tracked headcount is 822.
| Name | Role | Group |
|---|---|---|
Stephanie Wang | Director/us Commercial Lead, New Product Commercialization - Oncology And Immunology Pipeline | Leadership |
Natalia Callaway | Senior Medical Director, Product Development/early Research And Development Ophthalmology | Leadership |
Aaron Chan | Director | Leadership |
Qianru Li | Executive Director And Senior Associate General Counsel, Therapeutics IP Lead | Leadership |
Raymond Meng | Medical Director, Early Clinical Development | Leadership |
William Berglind | Senior Group Director | Leadership |
mike lanning | Senior Director Employer Account Executives | Leadership |
Michelle Byrtek | Senior Director, People And Product Leader, Data And Statistical Sciences | Leadership |
Maura Dickler | Vice President, Global Product Development Oncology, Breast And Gynecologic Cancers | Leadership |
Christian Luque | Regulatory Program Director | Leadership |
Ben Schwartz | Director, US Pipeline, Cardiovascular, Renal, Metabolism | Leadership |
Elena Bernedo Arzac | Senior Vice President, Global Product Strategy, Oncology | Leadership |
Michelle Santy | Program Director | Leadership |
Jesse Woodhull | Director Information Technology And Operational Technology (itot) | Leadership |
Lauren Cupps | Solid Tumor Marketing Team Director | Leadership |
Scott Kohler | Senior Director, Corporate Groups & Employee Relations | Leadership |
Natalie Abts | Head Of Human Factors Engineering - Device And Packaging Development Leadership | Leadership |
Rob Schilling | Clinical Program Director | Leadership |
Lauren Bush | Gcs Infrastructure & Architecture Director | Leadership |
Giulio Barteselli | Group Medical Director, Ophthalmology Product Development | Leadership |
754 more people are available in the full profile.
Complete people profiles for Spark Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Spark Therapeutics
Spark Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genable Technologies.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapy for Retinitis pigmentosa is developed using AAV vectors. | genable.net | Dublin, Ireland | 2001 | Mar 2016 | $15.15M |
Complete acquisition details for Spark Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Spark Therapeutics
6 dated milestones of Spark Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Spark Therapeutics is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series B, of $72.8M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Genable Technologies.
- Exit Acquired by Roche.
Competitors of Spark Therapeutics
Spark Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Spark Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Spark Therapeutics
The website of Spark Therapeutics (sparktx.com) receives about 2.9K visits a month and ranks #4,235,481 among all websites worldwide, #5,228 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▼ 27.3% vs previous month
- Unique visitors1.7K
per month
- Global rank#4,235,481
among all websites
- Category rank#5,228
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit2.0
- Average visit43 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Spark Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
nurix-inc.com | nurix-inc.com | 100% | – | ||
| inovio.com | 96% | 11.7K | #1,670,423 | View details | |
| novartis.com | 95% | 948.8K | #58,822 | View details | |
| roche.com | 94% | 1.3M | #42,219 | View details | |
| asgct.org | 76% | 116.5K | #347,191 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Spark Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Spark Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Spark Therapeutics
Complete news archive for Spark Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spark Therapeutics
Spark Therapeutics was founded in 2013.
Spark Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Spark Therapeutics is a funded company, having raised a total of $82.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Oct 2013.
Spark Therapeutics has 822 employees.
Annual revenue of Spark Therapeutics is $64.73M as on Dec 31, 2018.
Spark Therapeutics was founded in 2013 and is headquartered in Philadelphia, United States. Focus is placed on the biotechnology sector, where gene therapies for rare diseases are developed. Engineered adeno-associated viruses are used to deliver target gene sequences for treating RPE-65 mediated inherited retinal dystrophies, choroideremia, hemophilia A and B, and neurodegenerative conditions such as Battens disease. Operations center on advancing these therapies through research and clinical development.
Spark Therapeutics has made 1 acquisition, including Genable Technologies.
Spark Therapeutics has 8 investors. Key investors include Roche, Children's Hospital of Philadelphia, T. Rowe Price, Sofinnova, and Brookside Capital.
Spark Therapeutics operates through Spark Therapeutics, Inc..
Yes. Spark Therapeutics was acquired by Roche in February 2019.